Latest News

5 May

FDA approves FoundationOne Liquid CDx as companion diagnostic for Exkivity

Credit:  PublicDomainPictures from Pixabay.

The US Food and Drug Administration (FDA) has granted approval for Foundation Medicine’s FoundationOne Liquid CDx as a companion diagnostic for Takeda’s Exkivity (mobocertinib). 

Exkivity already secured approval from the FDA for locally advanced or metastatic non-small cell lung cancer adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. 

FoundationOne Liquid CDx is claimed to be the only blood-based comprehensive genomic profiling test that received the US regulator’s approval for detecting EGFR exon 20 insertion mutations to identify suitable patients to treat with Exkivity. 

This qualitative next-generation sequencing-based in vitro diagnostic test has the ability to analyse over 300 cancer-related genes for genomic alteration from a simple blood sample. It specifically analyses 324 genes by deploying circulating cell-free DNA. 

The prescription use-only test received FDA approval to report short variants in 311 genes, as well as a companion diagnostic to detect patients who are expected to benefit from treatment with specific therapies. 

3 May

Smith+Nephew receives contract for PICO wound therapy systems

Medical technology company Smith+Nephew has received an Innovative Technology contract from Vizient to supply its PICO single-use negative pressure wound therapy (sNPWT) systems.

PICO is a portable, easy-to-use, canister-free sNPWT system equipped with the Smith+Nephew soft port technology. The silicone-based, four-layer technology is designed to manage exudate from wounds by simultaneously evaporating and locking it away. 

This removes extra moisture away from the wound and peri-wound area. Furthermore, the technology provides compression to the peri-wound area, potentially improving tissue perfusion. 

Smith+Nephew NPWT vice-president and general manager Laura Ackerman said: “We are thrilled that our PICO System has been recognised by healthcare experts in receiving this distinguished Innovative Technology contract in the US. 

“Surgical site complications continue to be costly events that plague our patients and healthcare systems. Our PICO technology has been shown to reduce the risk of SSIs across multiple specialities, improving patient care and helping get them home sooner.” 

2 May

Hologic’s revenue falls to $1.02bn in Q2 2023

Global medical technology company Hologic reported a revenue of $1.02bn for the second quarter (Q2) ending 1 April 2023. 

The company witnessed a 28.5% decline in revenue compared to $1.43bn during Q2 (three-month period ended 26 March) of fiscal 2022. The fall in revenue was mainly attributed to significantly lower sales of Covid-19 assays, compared to the same period a year ago. 

The company’s total organic revenue, excluding Covid-19 revenue, grew by 20.2% during Q2 2023, compared to the prior year period. 

Gross margin declined by 880 basis points (bps) to 57.1% from 65.9% in Q2 2022, while operating margin decreased by 1,490bps to 26.5%. 

During the quarter, the diluted earnings per share (EPS) was $0.87 against $1.8 in the corresponding period in 2022. 

9 May

FDA grants breakthrough device status to Singlera’s liquid biopsy assay 

The US Food and Drug Administration (FDA) has granted breakthrough device designation to Singlera Genomics’ PDACatch liquid biopsy assay. 

The new DNA methylation-based assay is intended to identify pancreatic adenocarcinoma in individuals at high disease risk. 

PDACatch is based on the company’s MethylTitan platform, which deploys a library construction approach and methylation haplotypes to yield better conversion rates and cancer detection sensitivity. 

Previously, the technology was shown to enable the early identification of five cancer types four years before conventional diagnosis. 

The test is capable of identifying methylation patterns in circulating tumour DNA in blood, which originate from both early-stage pancreatic adenocarcinomas and precancerous pancreatic lesions such as intraductal papillary mucinous neoplasms and mucinous cystic neoplasms. 

It will facilitate early detection and intervention for high-risk PDAC patients. 

9 May

Siemens to distribute Scopio Labs’ digital imaging solutions platforms 

Siemens Healthineers has reached an agreement with Scopio Labs for the distribution of the latter’s Scopio X100 and Scopio X100HT imaging platforms across the world. 

Scopio X100 and Scopio X100HT provide full-field imaging and an artificial intelligence (AI)-powered decision support system with remote viewing capabilities. 

These imaging platforms complement Siemens’ systems such as the Atellica HEMA 570 and Atellica HEMA 580 analysers. 

Labs can use the combined platforms to achieve high-resolution, full-field viewing for peripheral blood specimens and AI-based morphological analysis with remote capabilities via the secure hospital network.  

Scopio digital cell morphology platforms enable the examination of patient blood cell samples digitally and remotely, rather than on a microscope slide. 

These platforms are designed for use in the central laboratory, alongside haematology analysers. A haematology analyser is used to run a sample from a patient.

Go to article: Home | AI is reimagining imaging, but how far can we go today?Go to article: Editor's letterGo to article: ContentsGo to article: Alleima Company InsightGo to article: AlleimaGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Apple RubberGo to article: mdi ConsultantsGo to article: In DepthGo to article: AI is reimagining imaging, but how far can we go today? Go to article: Understanding updates on medical device labelling Go to article: Mass spectrometry and photometry for rAAV vector characterisation   Go to article: More than just meetings? Zoom scales ambitions in telehealth Go to article: Breathing easy: How digital inhalers are changing asthma treatment  Go to article: The cost of companion diagnostics in oncology Go to article: Formacoat Company InsightGo to article: FormacoatGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: Foreword: ESG moves up the agendaGo to article: ESG is the most important theme of this decadeGo to article: A timeline of corporate ESGGo to article: The most pressing ESG concerns for the medical device industryGo to article: Key trends impacting ESG performance in the medical device sectorGo to article: Latest news: ESG in medical devicesGo to article: Q&A with GlobalData thematic analystGo to article: Sustainable supply chains: Clinical trials in a new era of limited resources  Go to article: GlobalData highlights the need for ESG commitment by medical device companies Go to article: Leading medical companies in the ESG theme Go to article: Environmental sustainability innovation: leading companies in biomedical 3D prinGo to article: Deal activity related to ESG in the medical industry since 2020Go to article: ESG hiring trends in the global medical industry since 2020 Go to article: ESG patent applications in the global medical industry since 2020Go to article: Mentions of ESG in medical industry company filings since 2020Go to article: GlobalData Thematic IntelligenceGo to article: Sponsored supplementsGo to article: WatlowGo to article: Mimotopes Company InsightGo to article: ListingsGo to article: EventsGo to article: Get ready for the Medical Device Network Excellence Awards Go to article: Buyer's GuidesGo to article: Next issue